Although this is the indication that currently appears on the Data Sheet, selpercatinib was originally approved by the EC for patients who had previously been treated with immunotherapy and/or platinum-based chemotherapy [49].Clinical evidence approval SNS indication #1: The approval of both indications is based on the results of the phase I/II LIBRETTO-001 (NCT03157128) study, which evaluated selpercatinib, separately, in patients with advanced NSCLC with RET oncogene fusion, treated and not previously treated with platinum-based chemotherapy. This evidence concerns the gene RET and non-small cell lung carcinoma.